Due to their innate tumour homing capabilities, in recent years, CTCs have been engineered to express therapeutic genes for targeted treatment of primary and metastatic lesions. Additionally, previous studies have incorporated optical or PET imaging reporter genes to enable noninvasive monitoring of therapeutic CTCs in preclinical tumour models. Here, we demonstrate for the first time, the ability of magnetic particle imaging (MPI) to sensitively detect systemically administered iron-labeled CTCs and to visualize tumour self-homing in a murine model of human breast cancer.
Introduction
Tumour self-homing describes a phenomenon where circulating tumour cells (CTCs) that have shed from a primary tumour into the circulation, can return to grow at their original tumour site. This concept was first described by Norton and Massagué in 2006 and is thought to be driven by both a leaky vasculature that permits CTC recruitment, as well as a permissive tumour microenvironment that promotes CTC survival and growth 1, 2 . Due to their tumour targeting capabilities, in recent years, self-homing CTCs have been repurposed as delivery vehicles for anticancer therapeutics. This has included the delivery of oncolytic viruses, pro-drug activatable suicide genes, and transgenes that alter the tumour microenvironment [3] [4] [5] [6] [7] [8] [9] . This strategy has shown exciting progress towards treating primary tumours, single organ metastases and most recently, multi-organ metastases however, further refinement is needed in order to optimize self-homing CTCs for potential clinical translation. Tools that enable the fate of systemically administered CTCs to be noninvasively monitored over time would provide valuable information about the kinetics and efficiency of CTC infiltration into tumours, their proliferation and persistence over time, any unwanted off-tumour accumulation, as well as information to better understand therapeutic response in individual subjects.
Cellular imaging can be used to noninvasively study a specific cell population or cellular process in vivo. Previous studies have used imaging reporter genes, namely bioluminescence imaging (BLI) 4, 9 and positron emission tomography (PET) reporters 7, 8 , to track CTCs in preclinical models.
For instance, in 2007, Power and colleagues used dual-enzyme BLI, a commonly used optical modality, to noninvasively monitor both the carrier cells (i.e., cancer cells) and their viral payload in vivo. By using this system, they demonstrate independent monitoring of cell vehicle distribution and virus associated luciferase enzymes. Our group has recently used dual BLI to visualize spontaneous whole-body breast cancer metastases expressing Renilla luciferase, and systemically administered theranostic CTCs expressing Firefly luciferase. Additionally, as a step towards tracking CTCs in patients, Reinshagen et al., recently demonstrated that the PET reporter gene, herpes simplex virus-thymidine kinase (HSV-TK) can be used to monitor the fate of therapeutic CTCs derived from glioblastoma.
An alternative method for tracking cells is to pre-label them with imaging probes prior to transplantation into the body [10] [11] [12] [13] [14] [15] [16] . These techniques are complementary to reporter gene techniques and often used for short term tracking of the initial arrest of cells at a target site, due to probe dilution during cell division. An advantage of probe-based tracking is that it does not require genetic engineering of cells, which may be more feasible for translational purposes. Moreover, probe-based cell tracking is often much more sensitive to low numbers of cells compared to reporter gene technologies due to the fact that large amounts of probe can be concentrated into each cell. Our group has previously shown MRI of cells loaded with superparamagnetic iron oxide nanoparticles (SPIONs) with single cell sensitivity in various mouse models 13, 14, 16 . We and others have used this extensively to track cell types such as cancer cells, stem cells and immune cells.
However, some limitations of SPION-based MRI are that SPIONs create a loss of signal and quantitation of signal loss and the number of iron-labelled cells in a particular region is challenging 11 . Magnetic particle imaging (MPI) is an emerging imaging technique that sensitively and specifically detects superparamagnetic iron oxide nanoparticles (SPIONs) [17] [18] [19] . In MPI, SPIONs result in positive signal and the signal strength is linearly proportional to the number of SPIONs, which allows for truly quantitative imaging. A few groups have started to explore the potential of MPI as a novel cell tracking technology with various SPIONs (e.g., ferumoxytol or ferucarbotran) [18] [19] [20] [21] . However, very few groups have explored the use of MPI to track the biodistribution of systemically administered SPION-labeled cells. In this work, we monitor the fate of SPION-labeled experimental CTCs in tumour bearing mice and demonstrate for the first time, the visualization of tumour self-homing in a mouse model of breast cancer with high sensitivity MPI.
Methods

Cell labeling
MDA-MB-231 and MDA-MB-231BR-eGFP cells were each maintained in Dulbecco's modified eagle media (DMEM) containing 10% fetal bovine serum (FBS) at 37 °C and 5 % CO2. For cell labeling, 2 x 10 6 adherent cells were incubated with 25 μg Fe/mL micron-sized paramagnetic ironoxide (MPIO) beads (0.9 μm in diameter, 63% magnetite, labeled with Flash Red; Bangs Laboratory, Fishers, IN, USA) for 24 hours. Cells were washed three times with Hanks balanced salt solution (HBSS) and then trypsinized with 0.25% Trypsin-EDTA. The cells were then collected and thoroughly washed three more times with HBSS to remove unincorporated MPIO before cell injection and in vitro evaluation. Cell labeling had no effect on cell viability, and labeling efficiency was assessed by Perl's Prussian blue (PPB) staining.
Animal Model
The animals were cared for in accordance with the standards of the Canadian Council on Animal 
MPI Acquisition
Full body MPI images of tumour-bearing mice were acquired 72 hours following intracardiac injection of MPIO-labeled CTCs (day 44). Images were collected on a Momentum TM scanner (Magnetic Insight Inc., Alameda, CA, USA) using the 3D high sensitivity scan mode. In this mode, tomographic images were acquired using a 3 T/m gradient, 35 projections and a FOV 12 x 6 x 6 cm, for a total scan time ~1 hour per mouse. Mice were anesthetized with 2% isoflurane in 100% oxygen during these scans. 3D high sensitivity images of ex vivo tumours were acquired using the same parameters.
MPI Calibration and Signal Quantification
To generate a calibration curve, a phantom was made with 1 μL aliquots of MPIO beads and imaged using the same parameters as in vivo images. The following samples of iron content were tested: 0.07 μg, 0.105 μg, 0.14 μg, 0.21 μg, 0.28 μg, 0.7 μg, 1.05 μg, 1.4 μg, 2.1 μg, and 2.8 μg of iron. Images were analyzed utilizing Horos imaging software (Annapolis, MD USA). To calculate the total MPI signal in each image set, signal intensities were set to full dynamic range to best represent the full range of signal in a specific region of interest (ROI; i.e. calibration samples or tumours), prior to manually outlining the signal. The signal intensities from the in vivo images had to be adjusted to visualize tumour signal, decreasing window level and width to compensate for the high liver signal (max = 0.133, min = 0.01). Areas of interest from in vivo 3D images were manually outlined, slice by slice, creating a 3D volume. These ROIs (determined from tumour signal) were copied and pasted onto the contralateral MFP of the same mouse to assure an equivalent volume of control tissue was used for quantification of signal. Total MPI signal was calculated by mean signal x volume(mm 3 ). Total MPI signal was plotted against iron content to derive calibration lines and quantify iron content in tumours and contralateral MFPs.
MRI Acquisition
MRI scans were performed on a 3 T MR750 clinical scanner (General Electric) equipped with a custom-built, insertable gradient coil and mouse brain solenoidal radiofrequency coil 13, 16 . Tumour samples were tightly placed in MR compatible tubes to avoid motion artifacts. Images were acquired using a balanced Steady State Free Precession (bSSFP) imaging sequence [Fast Imaging
Employing Steady State Acquisition (FIESTA) on the GE system] which has been previously optimized for iron detection 24 
Histology and immunohistochemistry
Following imaging, all mice were sacrificed by isoflurane overdose and perfused with 4% paraformaldehyde. Tumours were excised and placed in paraformaldehyde for an additional 24 hours. Fixed tissue was processed, paraffin embedded and cut into 10 μm sections. Select sections were stained for iron with Perl's Prussian blue (PPB) or stained for GFP by immunohistochemistry.
Statistical Analysis
Statistics were calculated using GraphPad Prism 7 Software. Pearson's rank correlation was used to determine the relationship between total MPI signal and iron content. In vivo data was expressed as mean ± SEM and analyzed by a Student's t test. Differences were considered statistically significant at *p < 0.05.
Results
In vitro studies Figure 1A shows the MDA-MB-232BR-GFP cell line was efficiently labeled with MPIO. The Perl's Prussian blue stain shows intracellular iron in blue within the breast cancer cells that appear pink. We acquired images of samples with known iron content to determine the relationship between MPI signal and iron content ( Figure 1B ). Samples were separated by 2cm on the MPI bed to allow for imaging of 5 samples per scan. A strong relationship between iron content and MPI signal was observed (R 2 = 0.974, p < 0.0001) ( Figure 1C ). These calibration curves were used to quantify iron content of MPIO labeled MDA-MB-231BR cells in in vivo and ex vivo images.
In vivo studies Figure 2A shows MPI images of tumour bearing mice 72 hours after receiving 5 x 10 5 MPIO labeled MDA-MB-231BR cells. These images were scaled to display the full dynamic range of signal across all mice. MPI signal can be clearly visualized in the lower right MFP tumour. Signal was also detected in lungs of some of the mice, likely due to iron labeled cells that were trapped in the lungs following intracardiac injection, as well as, signal in the abdomen, presumably due to iron content in the mouse feed. The distribution of MPI signal throughout the body can be visualized by scrolling through the complete 3D dataset (Video file 1). We found that iron content in the lower right MFP (tumour bearing) (M= 0.798 ± 0.184μg) was significantly higher than in the contralateral MFP (M= 0.318 ± 0.044μg). The average tumour volume measured by calipers was 230.6 ± 42.48mm 3 .
Ex vivo studies
MPIO labeled MDA-MB-231BR cells were also visualized within MFP tumours using ex vivo imaging (Figure 3) . In MPI images, the iron distribution of 3 different tumour samples of varying sizes were visualized ( Figure 3A/B ). The average iron content per tumour was 1.48 ± 0.24μg ( Figure 3C ). Iron labeled cells were also visualized as regions of signal void throughout tumours using iron-sensitive ex vivo MRI ( Figure 3D ). 
Microscopy and Immunohistochemistry
Mice were sacrificed 44 days after MFP cell injection. Iron labeled cancer cells were visualized within the MFP tumour using PPB staining ( Figure 4A) . Immunostaining of adjacent sections demonstrated that the location of GFP positive cells corresponded with the location of iron ( Figure   Figure 3 : Ex vivo tumour samples were placed in a 15mL falcon tube and imaged with MPI and MRI. A maximum intensity projection of MPI signal was overlaid onto a brightfield image for anatomical context (A/B). Individual slices from the 3D MPI data set were qualitatively assessed for correspondence with areas of signal void in MRI (C/D). 4B). This suggests the MPI and MRI signal we are seeing in iron-based imaging techniques is from iron-labeled, GFP expressing CTCs throughout the tumour.
Discussion
A number of different cell-based vectors have previously been developed for the targeted delivery of anti-cancer therapeutics to primary and metastatic lesions [25] [26] [27] [28] [29] [30] [31] . While some cell types have shown promise due to their innate homing capabilities (i.e. Immune cells and stem cells), new strategies to overcome intratumoural immunological barriers and on-target off-tumour effects are urgently needed. CTCs may represent a novel cell-based platform for therapy whereby, they are highly efficient at homing to established tumour sites, can be readily engineered and expanded ex vivo, and could be generated from an individual patient's tumour to avoid an unwanted immune response. Our group and others have shown exciting progress towards the development of selfhoming CTCs for the treatment of primary and metastatic lesions however, further study is warranted to optimize CTCs for clinical translation [3] [4] [5] [6] [7] [8] [9] . Here, we demonstrate for the first time, the In this work, we visualized iron-labeled MDA-MB-231BR-eGFP cells that had migrated to an MDA-MB-231 primary tumour, which we hypothesized may be due to a well-established tumour microenvironment. Previous work by Kim et al., has shown that an MDA-MB-231 tumour can produce chemoattractants, IL-6 and IL-8, that are capable of actively recruiting shed CTCs 32 .
Vilalta and colleagues have also shown in the murine 4T1 breast cancer model that irradiation of tumours induces the expression of granulocyte-macrophage colony stimulating factor (GM-CSF) that can act to enhance the recruitment of CTCs 33 . Their evidence suggests radiation induced selfhoming may act as a potential mechanism for cancer recurrence in the clinic. Future work will look to investigate how the production of these cytokines relates to the amount of CTC selfhoming, and whether we can visualize these differences over time with MPI.
In our model, the primary MDA-MB-231 MFP tumour had 41 days to grow prior to the administration of experimental CTCs. Despite observing a range in primary tumour size across mice, a clear relationship between MPI signal, representing the amount of CTC homing, and the size of the MFP tumour was not observed. Furthermore, the mouse having the smallest measured tumour burden (approximately 133mm 3 ) had MPI signal far above our estimated detection threshold, suggesting MPI may have the capability to detect much fewer CTCs than shown in this study. Future investigation should look to decrease tumour burden as well as alter the number of CTCs that are administered to better determine the sensitivity of MPI for detecting and longitudinally monitoring therapeutic CTCs in vivo. Additionally, the ratio of tumour cells to therapeutic CTCs needed for a therapeutic effect will be important when moving towards the treatment of whole-body metastases.
Our group and others have previously applied cellular MRI to track various iron-loaded cell types in vivo including immune cells, stem cells, cancer cells and pancreatic islets. Previous work has shown that labeling cancer cells with iron does not cause significant changes in cell viability, proliferation, apoptosis or metastatic efficiency making it an ideal probe for clinically relevant imaging studies 16, 34 . However, iron-based cell tracking techniques provide a limited imaging window as the probe gets diluted through cancer cell division 15 . In this work, we performed MPI at 72 hours following systemic injection of iron-labeled experimental CTCs. While we saw substantial MPI signal in all of the tumours, signal could be further enhanced by optimizing the timeline to visualize the maximum amount of self-homing prior to probe dilution. Furthermore, we observed MPI signal in the abdomen of mice as a result of having iron in the mouse feed. This was not detrimental to our study since the tumour bearing MFP is far enough away from the stomach to avoid signal overlap however, an iron-free diet should be considered for future studies that may include disease within that region.
Conclusions
In this work, we employed high sensitivity MPI to noninvasively visualize SPION-loaded experimental CTCs in tumour bearing mice. Further, we demonstrate a clinically relevant model of tumour self-homing whereby, SPION-labeled CTCs migrated, and were detected at the established MFP tumour site 72 hours following systemic administration. Future work will look to further build MPI as a valuable tool for visualizing whole-body tumour self-homing, which will be extremely valuable in understanding the fate of therapeutic CTCs and the potential mechanisms driving tumour self-homing throughout the body.
